With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug conjugate, Blenrep, developed with Pfizer (PFE) and Kyowa Kirin (OTCPK:KYKOF) ...

When it was sold in the U.S., Blenrep carried an FDA boxed warning for its ocular toxicity risks. GSK, optimistic about a global comeback, has put the drug’s peak sales estimate at more than 3 ...

Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple ...

Treatment of Blenrep (belantamab mafodotin) in combination with Velcade (bortezomib) plus dexamethasone significantly improved progression-free survival compared with standard treatment for patients ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed 1,2,3 First and only approved anti-BCMA-ADC for the treatment of multiple myeloma in ...

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...